Merck
Search Within
Applied Filters:
Keyword:'268569'
Showing 1-30 of 198 results for "

268569

" within Papers
Sort by Relevance
Henrik Holten-Rossing et al.
Breast cancer research and treatment, 152(2), 367-375 (2015-06-26)
In breast cancer, analysis of HER2 expression is pivotal for treatment decision. This study aimed at comparing digital, automated image analysis with manual reading using the HER2-CONNECT algorithm (Visiopharm) in order to minimize the number of equivocal 2+ scores and
Diana M Shih et al.
Journal of lipid research, 56(1), 22-37 (2014-11-08)
We performed silencing and overexpression studies of flavin containing monooxygenase (FMO) 3 in hyperlipidemic mouse models to examine its effects on trimethylamine N-oxide (TMAO) levels and atherosclerosis. Knockdown of hepatic FMO3 in LDL receptor knockout mice using an antisense oligonucleotide
Younghoon Kim et al.
PloS one, 10(4), e0122183-e0122183 (2015-04-16)
To find useful tools to evaluate the prognosis in colorectal carcinoma (CRC) patients, we investigated the prognostic values of tumor-infiltrating T lymphocyte subsets according to intratumoral subsites as well as clinical or molecular characteristics. Immunohistochemistry for CD8, CD45RO, and FOXP3
Song Nie et al.
Journal of proteome research, 14(2), 814-822 (2014-12-04)
Glioblastoma multiforme (GBM) is a highly aggressive brain tumor, with dismal survival outcomes. Recently, cancer stem cells (CSCs) have been demonstrated to play a role in therapeutic resistance and are considered to be the most likely cause of cancer relapse.
Wies van Roosmalen et al.
The Journal of clinical investigation, 125(4), 1648-1664 (2015-03-17)
Tumor cell migration is a key process for cancer cell dissemination and metastasis that is controlled by signal-mediated cytoskeletal and cell matrix adhesion remodeling. Using a phagokinetic track assay with migratory H1299 cells, we performed an siRNA screen of almost
Christian Schafroth et al.
Oncotarget, 6(39), 41453-41463 (2015-10-27)
VE1 is a monoclonal antibody detecting mutant BRAFV(600E) protein by immunohistochemistry. Here we aim to determine the inter-observer agreement and concordance of VE1 with mutational status, investigate heterogeneity in colorectal cancers and metastases and determine the prognostic effect of VE1
S Busch et al.
Oncogene, 34(1), 27-38 (2013-12-18)
Transforming growth factor-beta (TGF-β) is a pleiotropic cytokine with the capability to act as tumour suppressor or tumour promoter depending on the cellular context. TGF-beta receptor type-2 (TGFBR2) is the ligand-binding receptor for all members of the TGF-β family. Data
J M S Bartlett et al.
British journal of cancer, 113(5), 722-728 (2015-08-19)
TLE3, a nuclear transcriptional repressor downstream of WNT signalling pathways, has been hypothesised as predictive of benefit from adjuvant taxane. MA.21 tissue microarrays were constructed from 1097 out of 2104 (52%) patients. TLE3 staining by immunohistochemistry used validated methodology. Continuous
T T Seppälä et al.
British journal of cancer, 112(12), 1966-1975 (2015-05-15)
The objective of the study was to examine the role of microsatellite instability (MSI) and BRAF(V600E)mutation in colorectal cancer (CRC) by categorising patients into more detailed subtypes based on tumour characteristics. Tumour samples from 762 population-based patients with sporadic CRC
Alexey V Sorokin et al.
Cancer research, 75(9), 1846-1858 (2015-04-17)
The protein tyrosine phosphatase receptor PTPRN2 is expressed predominantly in endocrine and neuronal cells, where it functions in exocytosis. We found that its immature isoform proPTPRN2 is overexpressed in various cancers, including breast cancer. High proPTPRN2 expression was associated strongly
L Tomiyama et al.
Oncogene, 34(9), 1141-1149 (2014-03-26)
Dlg5 has been reported to participate in cancer progression; however, its role in prostate cancer still remains poorly understood. In this study, we demonstrate that Dlg5 is frequently downregulated in prostate cancer. We show here that Dlg5 is involved in
Stephanie H Gold et al.
Clinical psychology & psychotherapy, 22(4), 304-316 (2014-02-20)
This is the first study to explore the relationship between aspects of a therapists' personal therapy and the subsequent psychotherapy process and outcome they perform. The participants were 14 graduate clinicians with various experiences in personal therapy, who treated 54
Daniel Cuevas-Ramos et al.
The Journal of clinical endocrinology and metabolism, 100(1), 122-131 (2014-09-25)
GH-secreting pituitary adenomas exhibit heterogeneous natural history ranging from small tumors to large aggressive adenomas. To rigorously classify an acromegaly patient cohort defined by clinical, radiological, histopathological, and outcome characteristics. Cross-sectional study. Tertiary referral pituitary center. Subjects were selected from
Neerja Vajpayee et al.
Clinical lymphoma, myeloma & leukemia, 15(3), 159-163 (2014-12-03)
The mammalian target of rapamycin (mTOR) pathway regulates many major cellular processes and is implicated in an increasing number of neoplasms, including lymphoma. We correlated immunohistochemical expression of mTOR with germinal center and nongerminal center phenotype, B cell lymphoma-2 (bcl-2)
Roshan Sriram et al.
Breast cancer research : BCR, 17, 7-7 (2015-01-17)
Periostin (Postn) is a secreted cell adhesion protein that activates signaling pathways to promote cancer cell survival, angiogenesis, invasion, and metastasis. Interestingly, Postn is frequently overexpressed in numerous human cancers, including breast, lung, colon, pancreatic, and ovarian cancer. Using transgenic
Simone Bertz et al.
Virchows Archiv : an international journal of pathology, 465(6), 687-695 (2014-10-20)
Compared to other members of the fibroblast growth factor receptor (FGFR) family, only few studies investigate FGFR3 in tumour angiogenesis. We investigated the connection between angiogenesis and FGF/FGFR expression including FGFR3 mutation status in urothelial carcinomas. Immunohistochemistry was performed in
Philipp Jurmeister et al.
Lung cancer (Amsterdam, Netherlands), 87(2), 122-129 (2014-12-24)
ALK, MET and ROS1 are prognostic and predictive markers in NSCLC, which need to be implemented in daily routine. To evaluate different detection approaches and scoring systems for optimal stratification of patients eligible for mutation testing in the future, we
Frank K J Leusink et al.
Pathobiology : journal of immunopathology, molecular and cellular biology, 82(2), 58-67 (2015-05-30)
Oral squamous-cell carcinoma (OSCC) still has a poor prognosis. Lymph node metastasis (LNM) is a major determinant of treatment decisions and prognosis. Serine protease inhibitor Kazal-type 5 (SPINK5) is the inhibitor of kallikrein 5 (KLK5) and KLK7. SPINK5, KLK5 and
J L L Robinson et al.
Oncogene, 33(50), 5666-5674 (2013-12-03)
Castration-resistant prostate cancer (CRPC) continues to pose a significant clinical challenge with new generation second-line hormonal therapies affording limited improvement in disease outcome. As the androgen receptor (AR) remains a critical driver in CRPC, understanding the determinants of its transcriptional
Ion Cristóbal et al.
Clinical cancer research : an official journal of the American Association for Cancer Research, 21(2), 347-356 (2014-11-13)
SET is an endogenous PP2A inhibitor that might represent a novel molecular target for antitumor therapy. The aim of this study was to evaluate the molecular effects of SET deregulation and its potential clinical significance in metastatic colorectal cancer (mCRC).
Shafei Wu et al.
Thoracic cancer, 6(4), 413-420 (2015-08-15)
c-ros oncogene 1 (ROS1) rearrangement presents one of the newest molecular targets in non-small cell lung cancer (NSCLC). ROS1 rearrangement is predominantly found in adenocarcinoma cases and is exclusive to other oncogenes, such as epidermal growth factor receptor (EGFR), Kirsten
Jin Zhou et al.
Carcinogenesis, 36(4), 441-451 (2015-03-07)
Gastric cancer (GC) is the second leading cause of global cancer mortality worldwide. However, the molecular mechanism underlying its carcinogenesis and drug resistance is not well understood. To identify novel functionally important genes that were differentially expressed due to combinations
Sarah L Larsen et al.
PloS one, 10(2), e0118346-e0118346 (2015-02-24)
The underlying mechanisms leading to antiestrogen resistance in estrogen-receptor α (ER)-positive breast cancer is still poorly understood. The aim of this study was therefore to identify biomarkers and novel treatments for antiestrogen resistant breast cancer. We performed a kinase inhibitor
Vita Golubovskaya et al.
Journal of cancer research and clinical oncology, 141(9), 1613-1631 (2015-02-07)
Focal adhesion kinase is an important survival signal in cancer. Recently, we demonstrated that the autophosphorylation inhibitor of FAK, Y15, effectively inhibited cancer cell growth. We detected many cancer cell lines sensitive to Y15 and also detected several cell lines
Melissa R Junttila et al.
Science translational medicine, 7(314), 314ra186-314ra186 (2015-11-20)
Cancer stem cells (CSCs) are hypothesized to actively maintain tumors similarly to how their normal counterparts replenish differentiated cell types within tissues, making them an attractive therapeutic target for the treatment of cancer. Because most CSC markers also label normal
Sukhmani K Padda et al.
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 10(3), 500-508 (2014-11-18)
Blockade of the immune checkpoint programmed death receptor ligand-1 (PD-L1)/PD-1 pathway has well-established clinical activity across many tumor types. PD-L1 protein expression by immunohistochemistry is emerging as a predictive biomarker of response to these therapies. Here, we examine PD-L1 expression
Sebastian Trousil et al.
Cancer research, 74(23), 6867-6877 (2014-10-01)
Metabolic rearrangements subsequent to malignant transformation are not well characterized in endometrial cancer. Identification of altered metabolites could facilitate imaging-guided diagnosis, treatment surveillance, and help to identify new therapeutic options. Here, we used high-resolution magic angle spinning magnetic resonance mass
Qi Fei et al.
Nature communications, 6, 8651-8651 (2015-10-17)
SETDB1 is a histone H3K9 methyltransferase that has a critical role in early development. It is located within a melanoma susceptibility locus and facilitates melanoma formation. However, the mechanism by which SETDB1 regulates tumorigenesis remains unknown. Here we report the
Nicolas A Giraldo et al.
Clinical cancer research : an official journal of the American Association for Cancer Research, 21(13), 3031-3040 (2015-02-18)
Clear cell renal cell carcinoma (ccRCC) has shown durable responses to checkpoint blockade therapies. However, important gaps persist in the understanding of its immune microenvironment. This study aims to investigate the expression and prognostic significance of immune checkpoints in primary
Yun Hyun Huh et al.
Oncotarget, 6(15), 13060-13071 (2015-06-17)
Ectopic expression of Swiprosin-1, an actin-binding protein (also known as EF hand domain containing 2; EFHD2), enhanced motile protrusions associated with actin, such as lamellipodia and membrane ruffles. Swiprosin-1 levels were increased in various human cancer tissues, particularly at highly
Page 1 of 7
Page 1 of 7